Account:
Translating complex carbohydrate chemistries into unique, leading-edge products that enable researchers to explore and exploit glycobiology applications that promote human health.
Explore our extensive selection of functionalized GalNAc ligands with various alkyl and/or polyethylene glycol (PEG) linker/spacer systems. These enable facile introduction of GalNAc-based recognition elements onto a variety of molecules including but not limited to small molecules, surfaces, nanoparticles, peptides, proteins, antibodies, lipids and oligonucleotides.
Many critical roles of glycan elements on cell surface proteins and those bound to circulatory proteins are being recognized. Carbohydrates on proteins mediate a host of biological events including cell adhesion, immune system function, fertilization, cellular targeting as well as protein transport, stabilization, and half-life.
Pseudaminic Acid
25-Hydroxy Vitamin D3
1-α-Hydroxy Vitamin D3
1-α,25-Dihydroxy Vitamin D3
(β-D-GalNAc)3-PEG5-COOH
Tris-GalNAc: Triantennary GalNAc-β-Alanine-PEG3-Biotin
Tri-GalNAc-PEG2000-DSPE
Vitamin D3-d6
Sussex Research Laboratories Inc. has been working in the carbohydrate field for over two decades and have applied our synthetic strategies to seemingly countless problems. We have enabled application of complex carbohydrate systems for drug discovery, drug delivery, drug targeting, carbohydrate-based vaccine development, immunotherapy, therapeutic enhancement and diagnostic/bio-analytical assay development.
Drug Targeting – GalNAc
Targeted drug delivery of therapeutic payloads using N-acetylgalactosamine (GalNAc) conjugates that bind to Ashwell-Morell Receptors (asialoglycoprotein receptors or ASGPR) found in liver hepatocytes has become a leading delivery approach particularly for therapeutic oligonucleotides. Read more…
Vaccine Development – Polysaccharide Chemistry
Bacteria are highly glycosylated pathogens. Glycoconjugate vaccines have been proven to be a successful strategy to prevent infectious diseases with the global pneumococcal vaccine market estimated to be > $8 billion (USD) in 2021. Read more…
REQUEST A QUOTATION
Cancer – Glycans
It is well established that abnormal glycosylation on tumour cells compared to healthy cells is a hallmark of cancer and common to all cancers. Moreover, specific glycans on cell surface proteins actively drive tumour development and progression. New frontiers in drug discovery & development are being realized thanks to discoveries being made in glycobiology. Read more…
Monoclonal Antibody Development – Glycopeptides & Glycoconjugate Antigens
Therapeutic antibodies have become the predominant class of new drugs developed in recent years. Whether it is the antigen required to screen antibodies or to produce an antibody, we have the synthetic tools to produce carbohydrate antigens and their respective carrier protein conjugates. Read more…
Sussex Research Laboratories Inc. to Exhibit at TIDES USA 2022: Oligonucleotide & Peptide Therapeutics
May 4, 2022
Sussex Research Laboratories Inc., leading GalNAc and glycopeptide specialist, is excited to announce sponsorship of TIDES USA 2022: Oligonucleotide & Peptide Therapeutics! For over 25 years, we have enabled application of complex carbohydrate systems, including GalNAc and glycopeptides,...
Sussex Research Laboratories Inc. to Exhibit at The American Peptide Symposium 2022 – “Peptide Science at the Summit”
April 26, 2022
Great news! Sussex Research Laboratories Inc. will be exhibiting at The American Peptide Symposium (American Peptide Society) in Whistler, British Columbia, Canada! The symposium theme in 2022 is “Peptide Science at the Summit”. Sussex Research Laboratories Inc. is the global leader in...
Sussex Research Laboratories Inc. / Queen’s University collaboration receives support to develop novel small molecule therapies for COVID-19
May 21, 2020
Sussex Research Laboratories Inc. (Ottawa, Canada) today announced that Queen’s University and the Southeastern Ontario Academic Medical Organization (SEAMO) has awarded grants for two COVID-19 Rapid Response collaborations between Queen’s University (Dr. Stephen Archer; Department of Medicine, Dr....